Biocelect Pty News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Biocelect pty. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Biocelect Pty Today - Breaking & Trending Today
ATAGI update following weekly Covid meeting 26 August miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.
Novavax vaccine for adolescents aged 12 miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.
Novavax Nuvaxovid™ COVID-19 Vaccine Granted Expanded Provisional Approval in New Zealand for Adolescents Aged 12 Through 17 novavax.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from novavax.com Daily Mail and Mail on Sunday newspapers.
Nuvaxovid is New Zealand's only protein-based COVID-19 vaccine GAITHERSBURG, Md., Aug. 18, 2022 /PRNewswire/ Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that New Zealand's Medsafe has granted expanded provisional approval for Nuvaxovid (NVX-CoV2373) COVID-19 vaccine for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in adolescents aged 12 through 17. "We are pleased to offer a protein-based COVID-19 vaccine choice as a primary series to New Zealanders aged 12 and older and as a booster for adults 18 and older," said Stanley C. Erck, President and Chief Executive Officer, Novavax. "Providing Nuvaxovid now for adolescents may help increase vaccination rates amidst rising cases of COVID-19." The provisional approval was based on data from t ....
Nuvaxovid is New Zealand's only protein-based COVID-19 vaccine GAITHERSBURG, Md., Aug. 18, 2022 /PRNewswire/ Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that New Zealand's Medsafe has granted expanded provisional approval for Nuvaxovid (NVX-CoV2373) COVID-19 vaccine for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in adolescents aged 12 through 17. "We are pleased to offer a protein-based COVID-19 vaccine choice as a primary series to New Zealanders aged 12 and older and as a booster for adults 18 and older," said Stanley C. Erck, President and Chief Executive Officer, Novavax. "Providing Nuvaxovid now for adolescents may help increase vaccination rates amidst rising cases of COVID-19." The provisional approval was based on data from t ....